Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

Clinical Site, Sofia

Clinical Site, Sofia

Clinical Site, Sofia

Clinical Site, Bergen op Zoom

Clinical Site, Stara Zagora

Clinical Site, New York

Clinical Site, Berlin

Clinical Site, Berlin

Clinical Site, Berlin

Clinical Site, Mahlow

Clinical Site, Philadelphia

Clinical Site, Hamburg

Clinical Site, Lübeck

Clinical Site, Kiel

Clinical Site, Charleston

Clinical Site, Ormond Beach

Clinical Site, Miami

Clinical Site, Tampa

Clinical Site, St. Petersburg

Clinical Site, Nashville

Clinical Site, Bochum

Clinical Site, Indianapolis

Clinical Site, Münster

Clinical Site, Bad Bentheim

Clinical Site, Wroclaw

Clinical Site, Wroclaw

Clinical Site, Frankfurt

Clinical Site, Darmstadt

Clinical Site, Omaha

Clinical Site, Bellaire

Clinical Site, München

Clinical Site, Los Angeles

Clinical Site, Fountain Valley

Clinical Site, Beverly

Clinical Site, Boston

Clinical Site, Calgary

Clinical Site, Winnipeg

Clinical Site, Fredericton

Clinical Site, St. John's

Clinical Site, Hamilton

Clinical Site, London

Clinical Site, Markham

Clinical Site, Newmarket

Clinical Site, Peterborough

Clinical Site, Saskatoon

Clinical Site, Dresden

Clinical Site, Dublin

Clinical Site, Rotterdam

Clinical Site, Gdansk

Clinical Site, Krakow

Clinical Site, Lodz

Clinical Site, Olsztyn

Clinical Site, Ossy

Clinical Site, Ostrowiec Świętokrzyski

Clinical Site, Poznan

Clinical Site, Warsaw

Clinical Site, Warsaw